PCM
TCRT icon

Prelude Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Prelude Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-68
Closed -$27K – 2142
2014
Q3 		$27K Buy
+68
New +$32.8K ﹤0.01% 1676

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Prelude Capital Management's TCRT Position: Q4 2014 in Review

Prelude Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2014, closing a stake of 68 shares — an estimated $27K sold.

Prelude Capital Management first reported a position in TCRT in Q3 2014 and held it in 1 quarter. The position peaked at $27K in Q3 2014. 85 funds tracked by Wall St. Rank hold TCRT as of Q4 2014.

  • Prelude Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Prelude Capital Management sold 68 Alaunos Therapeutics shares in Q4 2014, an estimated $27K.
  • Prelude Capital Management first reported a position in Alaunos Therapeutics in Q3 2014 and held it in 1 quarter.
  • Prelude Capital Management's Alaunos Therapeutics position peaked at $27K in Q3 2014.
  • 85 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2014.

Based on Prelude Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.